NASDAQ: CSTL · Industrial Applications and Services · 14 alerts · CIK 1447362
Share price
$32.75Close, Nov 16
Market cap
$1.01B
Shares outstanding
30.82MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Castle Biosciences Inc filings on SEC EDGAR ↗
Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $112K of Stock
Tobin W. Juvenal, Chief Commercial Officer, sold 3,195 shares of Castle Biosciences Inc at $35.07 a share, worth $112K in total on Nov 11, 2026. Shares held after the trade: 32,737 (-8.9%).
Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $207K of Stock
Tobin W. Juvenal, Chief Commercial Officer, sold 6,116 shares of Castle Biosciences Inc at $32.67 to $35.04 a share (average $33.77) in 2 transactions, worth $207K in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 32,737 (-8.0%).
Castle Biosciences reported net revenues of $102.9 million for the third quarter of 2026, up from $83.0 million in 2025. Despite the revenue growth, the company realized a net loss of $4.1 million for the quarter, primarily driven by increased operating expenses in selling, general, and administrative functions.
Castle Biosciences reported Q3 2026 revenue of $102.9 million, a 24% increase year-over-year, driven by strong volume growth in its TissueCypher test. The company raised its full-year 2026 revenue guidance to a range of $385-395 million and reported a net loss of $4.1 million for the quarter.
Term
Q3 2026
“Our team delivered another strong quarter, reflecting consistent execution across our portfolio. TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025.”
Derek Maetzold, president and chief executive officer of Castle Biosciences
Castle Biosciences Pres. & Chief Exec. Officer Derek J. Maetzold Sells $523K of Stock
Derek J. Maetzold, Pres. & Chief Exec. Officer, sold 14,496 shares of Castle Biosciences Inc at $36.01 to $36.81 a share (average $36.10) in 6 transactions, worth $523K in total on Nov 2, 2026. Shares held after the trade: 1,396 (-18.9%).
Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $240K of Stock
Tobin W. Juvenal, Chief Commercial Officer, sold 6,578 shares of Castle Biosciences Inc at $35.58 to $36.62 a share (average $36.42) in 2 transactions, worth $240K in total on Oct 28, 2026. Shares held after the trade: 38,853 (-12.1%).
Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $109K of Stock
Tobin W. Juvenal, Chief Commercial Officer, sold 3,288 shares of Castle Biosciences Inc at $33.08 a share, worth $109K in total on Oct 26, 2026. Shares held after the trade: 45,431 (-6.7%).
Castle Biosciences Pres. & Chief Exec. Officer Derek J. Maetzold Sells $463K of Stock
Derek J. Maetzold, Pres. & Chief Exec. Officer, sold 14,496 shares of Castle Biosciences Inc at $31.91 a share, worth $463K in total on Oct 19, 2026. Shares held after the trade: 4,114 (-39.8%).